FCX-013

FCX-013 · Castle Creek Biosciences, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FCX-013, covering 2022-06-24 to 2022-06-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) [Phase 1, Phase 2]

See pricing